Alopecia likewise called as balding or sparseness is an ailment that alludes to loss of hairs from head or any piece of the body. The condition can happen in both male and female and at whatever stage in life. There are five significant sort of alopecia in particular; alopecia areata, androgenic alopecia, ciatricial alopecia, foothold alopecia, and alopecia totalis. Alopecia areata is a typical immune system problem wherein the insusceptible arrangement of body assaults the solid hair follicle prompting hair fall. Androgenic alopecia otherwise called male example hairlessness and female example going bald is an extremely normal kind of alopecia and influences numerous people at some phase of life. Ciatricial alopecia otherwise called scarring alopecia is a condition wherein hair follicles are annihilated and supplanted by scar tissue. There are just not many endorsed treatment drugs showed for the treatment of alopecia. For example, Minoxidil, Finasteride, and Cyclosporine.
In recent past, regulatory bodies have approved novel drugs for treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in near future. Approval of novel drugs and presence of robust drug pipeline is expected to drive global alopecia treatment market growth in near future. For instance, in January 2018, Concert Pharmaceuticals, Inc., a U.S.-based company received Fast Track designation from U.S. Food and Drug Administration (FDA) for its novel product CTP-543. CTP-543 is a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata.
According to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is most prevalent autoimmune disorder and the second most prevalent hair loss disorder with around 2% population worldwide suffering from androgenetic alopecia. According the data published by Arch Argent Pediatr, in 2017, the prevalence of Alopecia areata is higher in the age group of 10 and 25 years and around 60% of people under these age group suffers from Alopecia areata. Therefore, high prevalence of alopecia is expected to propel demand for its treatment drugs, which in turn is expected to create a lucrative environment for the global alopecia treatment market growth in near future.
Key players operating in the alopecia treatment market include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline Plc., Daiichi Sankyo, Inc., Cipla Limited, and others.
Read more @ https://digitalinsightscmi-blog.blogspot.com/2021/09/approval-of-novel-drugs-and-presence-of.html
